Novo Nordisk Sees First-Half U.S. Launch of Tresiba

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

Jan. 31 (Bloomberg) -- Jesper Brandgaard, chief financial officer of Novo Nordisk A/S, discusses the company's fourth-quarter profit reported today, growth expectations for the insulin market and the outlook for U.S. approval of its Tresiba diabetes treatment. He speaks from Copenhagen with Francine Lacqua on Bloomberg Television's "The Pulse." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change